As depicted in Figure 1(c), MS patients showed almost a doubled concentration of active MMP-9 compared to OND controls (p = 0.009), whereas the levels of active MMP-2 did not differ (Figure 1(d), median (interquartile range): 4.7 (2.3–11.4) and 5.1 (2.7–10.4) for OND and MS patients, resp.; p = 0.713). This evidence concerns the gene MMP9 and myeloid sarcoma.